Outcome metrics
| . | Product I, n = 116 . | Product II, n = 164 . | Product III, n = 168 . | Product IV, n = 82 . | P . |
|---|---|---|---|---|---|
| Clinical outcome | |||||
| Days of fever post-IVIG, median (IQR) | 0 (0-1) | 1 (0-2) | 0 (0-2) | 1 (0-2) | .006 |
| Retreatment rate/IVIG failure, n (%) | 17 (15) | 54 (31) | 42 (24) | 20 (24) | .01 |
| Acute readmission, n (%) | 6 (5) | 19 (11) | 16 (9) | 9 (11) | .32 |
| Coronary outcome, n (%) | n = 115 | n = 164 | n = 168 | n = 82 | |
| No CAA z <2.5 | 103 (90) | 144 (88) | 144 (86) | 69 (84) | |
| CAA z >2.5 | 12 (10) | 20 (12) | 24 (14) | 13 (16) | .66 |
| . | Product I, n = 116 . | Product II, n = 164 . | Product III, n = 168 . | Product IV, n = 82 . | P . |
|---|---|---|---|---|---|
| Clinical outcome | |||||
| Days of fever post-IVIG, median (IQR) | 0 (0-1) | 1 (0-2) | 0 (0-2) | 1 (0-2) | .006 |
| Retreatment rate/IVIG failure, n (%) | 17 (15) | 54 (31) | 42 (24) | 20 (24) | .01 |
| Acute readmission, n (%) | 6 (5) | 19 (11) | 16 (9) | 9 (11) | .32 |
| Coronary outcome, n (%) | n = 115 | n = 164 | n = 168 | n = 82 | |
| No CAA z <2.5 | 103 (90) | 144 (88) | 144 (86) | 69 (84) | |
| CAA z >2.5 | 12 (10) | 20 (12) | 24 (14) | 13 (16) | .66 |
CAA, coronary artery aneurysm; IQR, interquartile range.